STATISTICAL ANALYSIS PLAN 
 
 
Official Title:  A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot 
Consistency of Sci-B-Vac‚Ñ¢ in Adults (CONSTANT) 
  
 
Protocol Identifying Number:  Sci-B-Vac‚Äì002  
 
 
Study ID: [REMOVED] 
  
Version :  2.0  
 
 
Date of Version :  December 4, 2019  
 
 
Study Sponsor:  
VBI Vaccines Inc.  
[ADDRESS_184396] Ottawa, ON K1V 1C1 Canada  
Telephone: ([PHONE_2145]  
  
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 1 of 37  
  
STATISTICAL ANALYSIS PLAN 
 
    
 
  
 
Sci-B-Vac-002 
 
 
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac‚Ñ¢ in 
Adults (CONSTANT) 
 
  
 
 
 
 
 
Version: Final 2.0 
Date: 04/Dec/2019 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 2 of 37  
 REVISION HISTORY 
 
Version Version Date Author Summary of Changes Made 
Draft 1.0 16May2017 Yongmei Zhou 
(Biostatistician) New Document 
Final 1.0 See Footer Yongmei Zhou 
(Biostatistician) 1. Delete age derivation since date of birth 
is collected as MMYYYY 
2. Wording to match protocol 
3. Updated based on protocol version 2.0 
Draft 1.1 See Footer Hong Wang 
(Biostatistician) 1. Added bar plot of SPR on Days 168, 
Day 196 and 336 
2. Clarified change from baseline for 
hematology and biochemistry calculated 
for SSA only 
3. Added summary table for PE 
4. Added Section 6.3.4 to define the 
nominal study visit and analysis visit 
5. Updated the protocol version that this 
SAP is based on. 
6. Corrected the typo of ‚ÄúMiettnen and 
Nurminen method‚Äù to ‚ÄúMiett inen and 
Nurminen method‚Äù 
7. Clarified the TEAE definition to be 
consistent with 2nd safety endpoint in 
the protocol. 
8. Updated the SAS version that will be 
used to version 9.3 or later. 
9. Removed the appendixes because they 
are already included in the previous 
sections of the SAP. 
Draft 1.2 See Footer Hong Wang 
(Biostatistician) 1. Updated the sample size in Section [ADDRESS_184397] 
was identified by [CONTACT_1034] 
3. Added subgroup analysis by 
[CONTACT_1606]/region for the assessment of 
consistency in treatment effects across countries/regions 
4. Provided details how the 
immunogenicity data will be used to define seroprotection and how the upper limit value will be used as continuous 
variables 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/[ADDRESS_184398] vaccination 
through the date of end study 
6. Added an additional exploratory analysis 
per Sponsor‚Äôs request as follows: To 
determine whether the SPR after 2 
vaccinations with Sci-B-Vac‚Ñ¢, 
evaluated 20 weeks after the second 
vaccination (just prior to receiving the third vaccination), is non-inferior to the 
SPR [ADDRESS_184399] 
vaccination with Engerix-B¬Æ. 
7. Added sensitivity analysis based on ITT 
in the secondary objective analyses 
Draft 1.3 See Footer Hong Wang 
(Biostatistician) Removed the out of window at V2 as a major PD 
causing exclusion from PPS in Section 6.2.5. 
The sponsor doesn‚Äôt think that it will affect 
immunogenicity analysis. 
Draft 1.4 See Footer Hong Wang 
(Biostatistician) Added visit window for immunogenicity data 
per Sponsor‚Äôs request 
Draft 1.5 See Footer Andreana Robertson Modified PAREXEL signature [CONTACT_3264] (changed 
biostatistician). 
Removed strikethroughs (text that should be 
deleted but wasn‚Äôt marked for deletion in 
tracked-changes). 
Removed immunogenicity analysis visits 
description (which included Table 1) from Section 6.3.4; adjusted subsequent table numbers 
accordingly. 
Updated verbiage in Section 6.3.8 to clarify that 
disposition summaries are done overall as well as by [CONTACT_1570], with the exception of 
screened and screen fail counts. 
Draft 1.6 See Footer Andreana Robertson Added another per protocol set, PPS1 (no 
exclusions due to out-of-window visit 3 and/or visit 4) for primary endpoint analysis. 
Final 2.0 See Footer Andreana Robertson Up-versioned to Final 2.0. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 4 of 37  
 SIGNATURE [CONTACT_1783] - VBI VACCINES INC. 
Declaration 
 
The undersigned has/have reviewed and agree to the statisti cal analyses and procedures of this clinical study, as 
presented in this document. 
 
 
  
 
 
 
December 4, 2019 
 
Date (DD Mmm YY) 
 
Chief Medical Officer 
  
 
 
December 4, [ADDRESS_184400]. Vlad Popovic Date (DD Mmm YY) 
 
VP, Clinical Development and Medical Affairs 
 
   
 
December 4, 2019 
Johanna Spaans Date (DD Mmm YY) 
 
Clinical Epi[INVESTIGATOR_158773]. Francisco Diaz-Mitoma 

PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 5 of 37  
 SIGNATURE [CONTACT_1783] - PAREXEL 
Declaration 
 
The undersigned agree to the statistical analyses and procedures of this clinical study. 
If this document has been signed electronically, signature(s) and date(s) are present at the end of the document: 
Document prepared and approved by: 
 
  
 
  
 
 
[CONTACT_158783], MS Date (DD Mmm YY) 
 
Principal Biostatistician 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/[ADDRESS_184401] .................................................................................. 8 STATISTICAL ANALYSIS PLAN ............................................................................................. 10 1. STUDY OBJECTIVES ................................................................................................... 10 
1.1 Primary Objective ............................................................................................... 10 
1.2 Secondary Objectives ......................................................................................... 10 
1.3 Exploratory Objectives ....................................................................................... 11 
2. STUDY DESIGN ............................................................................................................ 11 
3. STUDY POPULATION .................................................................................................. 12 
4. STATISTICAL BASIS FOR SAMPLE SIZE ................................................................. 13 
5. RANDOMIZAT ION ....................................................................................................... 14 
5.1 Definition of Vaccination/Randomization Errors .............................................. 14 
6. STATISTICAL ANALYSIS CONVENTIONS .............................................................. 15 
6.1 Analysis Variables .............................................................................................. 15 
6.1.1 Derived and Computed Variables ................................................................... 16 
6.2 Analysis Sets ...................................................................................................... 18 
6.2.1 All Enrolled Set ............................................................................................... 18 
6.2.2 Safety Set ........................................................................................................ 18 
6.2.3 Intent-to-Treat (ITT) ....................................................................................... 19 
6.2.4 Full Analysis Set (FAS) .................................................................................. 19 
6.2.5 Per Protocol Sets ............................................................................................. 19 
[IP_ADDRESS]  Per Protocol Set 1 (PPS1) ................................................................ 19 
[IP_ADDRESS]  Per Protocol Set 2 (PPS2) ................................................................ 20 
6.2.6 Sub-study Analysis  Set (SSA) ......................................................................... 20 
6.2.7 Sub Groups ...................................................................................................... 20 
6.3 Statistical Analysis Methods .............................................................................. 21 
6.3.1 Listings and Descript ive Statistics .................................................................. 21 
6.3.2 Statistical Signif icance Level .......................................................................... 21 
6.3.3 Software .......................................................................................................... 21 
6.3.4 Study Visits ..................................................................................................... 21 
6.3.5 Missing Data ................................................................................................... 22 
6.3.6 Interim Analysis .............................................................................................. 22 
6.3.7 Protocol Deviations ......................................................................................... 22 
[IP_ADDRESS]  Definition of Protocol Deviation ..................................................... 22 
[IP_ADDRESS]  Determination of Protocol Deviations ............................................. 23 
[IP_ADDRESS]  Exclusions of Individual Values for Safety Analysis ...................... [ADDRESS_184402] Disposition ......................................................................................... 24 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/[ADDRESS_184403] ......................................... 25 
6.3.13  Immunogenicity .............................................................................................. 25 
[IP_ADDRESS]  Primary Hypothesis.......................................................................... 26 
[IP_ADDRESS]  Statistical Methods for Primary Immunogenicity Analyses ............. 26 
[IP_ADDRESS]  Secondary Objective Analyses ........................................................ 27 
[IP_ADDRESS]  Exploratory Objective Analyses ...................................................... 28 
6.3.14  Safety Analysis ................................................................................................ 29 
[IP_ADDRESS]  Completer Analysis on Solicited Adverse Events............................ 29 
[IP_ADDRESS]  Solicited Local, Systemic and Other Adverse Events ...................... 30 
[IP_ADDRESS]  Unsolicited Adverse Events ............................................................. 33 
[IP_ADDRESS]  Clinical Safety Laboratory Tests (Hematology, Biochemistry and 
Urinalysis)........................................................................................ 35 
[IP_ADDRESS]  Vital Signs ....................................................................................... 36 
[IP_ADDRESS]  Physical Examination ...................................................................... 36 
7. REFERENCES ................................................................................................................ 37 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/[ADDRESS_184404] 
 
Abbreviation / Acronym Definition / Expansion 
AE Adverse event 
ANCOVA Analysis of covariance 
BLQ Below the lower limit of quantification 
BMI Body Mass Index Bpm Beats per minute 
CI Confidence interval 
CSP Clinical Study Protocol 
CSR Clinical Study Report 
CV Coefficient of variation 
CVID 
Common variable immune deficiency 
DBP Diastolic blood pressure 
eCRF Electronic Case Report Form 
FDA Food and Drug Administration 
FAS Full analysis set 
GMC Geometric mean concentration 
HBsAg Hepatitis B surface antigen HIV Human immunodeficiency virus 
HR Heart rate 
IP Investigational Product 
IWRS Interactive web response system LQ Limit of quantification 
MCAR Missing completely at random 
MedDRA Medical Dictionary for Regulatory Activities 
NK Not known 
NOCI New onset of chronic illness 
PD Protocol deviation 
PPS Per Protocol Set 
SAE Serious adverse event 
SAP Statistical Analysis Plan 
SBP Systolic blood pressure 
SD Standard deviation or single dose 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 9 of 37  
  
Abbreviation / Acronym Definition / Expansion 
SE Standard error of the mean 
SOC System Organ Class SPR Seroprotection rate 
SSA Sub-study Analysis Set 
S[LOCATION_003]R Suspected unexpected serious adverse reactions 
TEAE Treatment-emergent adverse event 
TLF Tables, Listings and Figures 
VBI VBI Vaccines Inc 
WHO-DD World Health Organization - Drug Dictionary 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/[ADDRESS_184405] an (SAP) details the statis tical methodology to be used in analyzing study data 
and outlines the statistical programming specifications for the Tables, Listings and Figures (TLFs). It 
describes the variables and populati ons, anticipated data transformati ons and manipulations and other 
details of the analyses not provided in  the Clinical Study Protocol (CSP). 
 
The analyses described are ba sed on CSP V4.0, dated 09May2018. 
The SAP will be finalized prior to database unblinding and describes the statistical analysis as it is foreseen when the study is being planned. If circ umstances should arise during the study rendering this 
analysis inappropriate, or if improved methods of analysis should ar ise, updates to the analyses may be 
made and this SAP will be amended. Any deviations from the SAP after database  unblinding, reasons 
for such deviations and all alterna tive or additional statistical analyses that may be performed, will be 
described in the clinical study report (CSR). 
 
1. STUDY OBJECTIVES 
 
1.1 Primary Objective 
 
To demonstrate the manufacturing equivalence, in terms of imm unogenicity, of th ree independent 
consecutive lots of the Sci-B-Vac‚Ñ¢ [ADDRESS_184406] vaccination. This obj ective will be met if the 
following condition is satisfied: 
x The upper and lower bound of the two sided 95% CI of the geometric mean concentration (GMC) of 
anti-HBs ratios [ADDRESS_184407] vaccination, for all three pairwise comparisons (GMC of anti- 
HBs in group A/GMC of anti-HBs in group B, GM C of anti-HBs in group A/GMC of anti-HBs in 
group C, GMC of anti-HBs in group B/GMC of anti-HBs in group C) are within [0.67, 1.5]. 
 
1.2 Secondary Objectives 
Immunogenicity 
To demonstrate that the SPR 4 weeks after completion of the three-dose regimen of Sci-B-Vac‚Ñ¢ is non- 
inferior to a three-dose regimen of Engerix-B¬Æ, i. e. the lower bound of the 95%  two-sided confidence 
interval (CI) of the difference between the SPR Sci- B-Vac‚Ñ¢ arm minus the SPR in the Engerix-B¬Æ arm, 
achieved [ADDRESS_184408] vaccination will be > -5. 
Safety 
x To assess the safety and reactogenicity of Sci-B-Vac‚Ñ¢ compared to Engerix-B¬Æ 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 11 of 37  
 1.3 Exploratory Objectives 
The following are exploratory objectives: 
x To assess the Geometric Mean Concentration (GMC) of anti-HBs in serum after [ADDRESS_184409] vaccin ation with Sci-B-Vac‚Ñ¢ 
or Engerix-B¬Æ, on Study Days 168 and 336, respectively. 
x To assess the seroprotection rate af ter [ADDRESS_184410] vaccination with Sci-B-V ac‚Ñ¢ or Engerix-B¬Æ, on Study Days 168 and 336, 
respectively. Seroprotection is defined as anti-HBs levels ¬ï 10mIU/mL in serum. Seroprotection Rate 
(SPR) is the percentage (%) of subjects achieving seroprotection. 
x To assess the Proportion of subj ects achieving anti-HBs levels ¬ï 100mIU/mL in serum, as a measure 
of an especially robust immune response, on Study Days [ADDRESS_184411] vaccination with Sci-B-Vac‚Ñ¢  or Engerix-B¬Æ, and on Study Day 336. 
x To assess the rate of non-response on Study Day 196, [ADDRESS_184412] vaccination with Sci-B- 
Vac‚Ñ¢ or Engerix-B¬Æ. Rate of non-response is de fined as the proportion of subjects not attaining 
anti-+%VOHYHOV¬ïP,8P/LQ  serum.
x To assess SPR, GMC and rate of non-response in sub-groups of interest (e.g. BMI > 30), [ADDRESS_184413] vaccination with Sci-B-Vac‚Ñ¢ or Engerix-B¬Æ. 
x To determine whether the SPR after 2 vaccinations with Sci-B-Vac‚Ñ¢, evaluated 20 weeks after the 
second vaccination (just prior to receiving the thir d vaccination), is non-inferior to the SPR [ADDRESS_184414] vaccination with Engerix-B¬Æ. 
 
2. STUDY DESIGN 
This is a double-blind 4-arm randomized study. Subj ects age 18-45 years will be randomly assigned to 
one of 3 lots of Sci-B-Vac‚Ñ¢ or to Engerix-B¬Æ with a ratio 1:1: 1:[ADDRESS_184415] Hepatitis B vi rus (HBV), according to a three-dose immunization 
schedule and followed for [ADDRESS_184416] (assuming a screening period of 28 days  or 4 weeks) is 364 days or 52 weeks. 
 
The scheme of the study design is as Figur e 1. For further details please refer to section 3.1 of the 
Protocol . 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 12 of 37  
  
Figure 1: Schematic of Study Design 
  
 
 
 
3. STUDY POPULATION 
Per protocol, the study population w ill consist of approxima tely 3200 adult subjects (18-45 years) in at 
least 30 study centers in the E.U., Canada and the U. S. of all races and ethni c groups meeting all the 
inclusion criteria and none of th e exclusion criteria. The fina l study population consisted of 
approximately 2800 adult subj ects after an early closure to enrollment (see Section 4 ). 
Inclusion criteria 
Subjects must meet all the following criteria: 
1. Any gender. 
2. Age 18-45 years. 
3. Healthy, as determined by a physical examin ation and values of laboratory tests. 
4. If female: a) either not of childbearing potential, defined as postmenopausal for at least 1 year or 
surgically sterile (bilateral t ubal ligation, bilateral oophorectomy or  hysterectomy), OR b) is of 
childbearing potential and must agr ee to use an adequate birth c ontrol method during the screening 
period and until the end of her par ticipation in the study (effective bi rth control includes: 1) hormonal 

PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 13 of 37  
 (implant, oral, vaginal, transderma l) contraceptives; 2) diaphragm with spermicide, condom (with or 
without spermicide); 3) in tra-uterine devices; and 4) vasectomy of  male partner; 5) abstinence from 
penile-vaginal intercourse (if the preferre d and usual lifestyle of the subject)). 
5. Able and willing to give informed consent. 
Main Exclusion criteria 
Main exclusion criteria are listed below, for the complete list of exclusion criteria please refer to section  
4.1.2 of the Protocol . Participants meeting any of the exclusion criteria will be excluded. 
1. Previous vaccination with any HBV vaccine (licensed or experimental). 
2. Treatment by [CONTACT_158784] w ithin 30 days of enrollment including but not limited to 
corticosteroids at a dose that is higher than an or al or injected physiological  dose, or > 20 mg /day 
prednisolone equivalent (Inhaled and topi[INVESTIGATOR_14271]). 
3. History of immunological function impairment,  including but not limited to: a) autoimmune 
diseases (e.g., multiple sclerosis, type [ADDRESS_184417]'s or Basedow‚Äôs disease, immune thrombocytopenic purpura, autoimmune 
hemolytic anemia, autoimmune he patitis, psoriasis, vitiligo, vasc ulitis, Guillain-Barr√© syndrome, 
Addison‚Äôs disease, Bell‚Äôs Palsy and Alopecia Areata); 
b) secondary immunodeficiency disorders (e.g. Acqu ired Immunodeficiency Syndrome caused by 
[CONTACT_158785] (HIV/A IDS), solid organ tran splant, splenectomy); 
c) primary immunodeficiency disorders (e.g. comm on variable immune deficiency (CVID), 
Defective phagocytic cell func tion and neutropenia syndromes , complement deficiency). 
4. Pregnancy or breastfeeding. 
5. Immunization with attenuated vaccines (e.g. MMR) within 4 weeks prior to enrollment. 
6. Immunization with inactivated vaccines (e.g. in fluenza) within 2 weeks prior to enrolment. 
 
4. STATISTICAL BASIS FOR SAMPLE SIZE 
The sample size for this study is driven by [CONTACT_158786]- to-lot consistency requireme nt. A total of 800 subjects 
in each of the three Sci-B-Vac‚Ñ¢ lots will provide at least 90% power to ensure that the 95% confidence 
interval for each pairwise difference (GMC of anti-HBs in group A/GMC of anti-HBs in group B, GMC 
of anti-HBs in group A/ GMC of anti-HBs in group C, GMC of anti-HBs in group B/ GMC of anti-HBs 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 14 of 37  
 in group C) in normalized log10 (G MC) will have a lower bound that is >-0.176 and an upper bound that 
is <0.[ADDRESS_184418] deviation LV¬îWKLVFRUUHVSRQGVWRWKHWUXH*0&UDWLRIDOOLQJEHWZHHQ 
2/3 and 3/2. With an active co mparator arm of Engerix-B¬Æ of equal size (n=800), the total sample size 
of the study is 3,200. 
If lot-to-lot consistency is demonstr ated, all three Sci-B-Vac‚Ñ¢ lots will be pooled together to test that 
the Seroprotection Rate ( SPR) four weeks after completion of the three-dose regimen of Sci-B-Vac‚Ñ¢ is 
non-inferior to a three-do se regimen of Engerix-B¬Æ. Assuming 10% of the subjects are non-evaluable 
(i.e., 2880 are evaluable, with 2160 randomized  to Sci-B-Vac‚Ñ¢ and 720 to Energix-B¬Æ), a two-sided 5% 
significance level and a non-inferiority margin of ‚Äì 5%, the non-inferiority test  will have > 90% power. 
The following table provides the estimated power unde r different assumptions of the SPR four weeks 
after completion of the three-dose regimens. 
Response in Energix-B¬Æ 
(N=720) Response in Sci-B-VacTM 
(N=2160)  
Power 
80% 85% 99% 
85% 85% 92% 
90% 95% 99% 
In October 2018, enrollment was closed early fo r non-safety-related re asons after 2838 were 
randomized to the study. With appr oximately 700 subjects in each of the three Sci-B-Vac‚Ñ¢ lots and 
700 subjects in comparator arm of Engerix-B¬Æ, the sample size will provide > 80% power to evaluate 
both the primary objective of lot to  lot consistency of the three Sc i-B-Vac lots, and the secondary 
objective of non-inferiority of  Sci-B-Vac‚Ñ¢ vs Engerix-B¬Æ. 
 
5. RANDOMIZATION 
A statistician who is not involved in the clinical as pects of the study will generate a permuted blocked 
randomization list for each site. Ra ndomization will be via a web-base d IWRS, stratified by [CONTACT_91294]. 
The site pharmacy and/or unblinded study center staff will receive a no tification of the randomization, 
which should be filed in a locked area/ computer folder not accessed by [CONTACT_91329]. 
5.1 Definition of Vaccination /Randomization Errors 
 
The list below provides some examples of potenti al errors that may occur during vaccination: 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 15 of 37  
 ∆ì Subjects vaccinated with a Sci-B-Vac‚Ñ¢ lot different from the one assigned Sci-B-Vac‚Ñ¢ lot at 
randomization. 
∆ì Subjects vaccinated with the correct Sci-B-Vac‚Ñ¢ lot but containing a lower volume. 
∆ì Subjects vaccinated with a vaccine differ ent from the one assigned at randomization. 
Please see section 6 of this document for a complete guidan ce on how vaccination/randomization errors 
are handled in the statistical analysis. 
 
6. STATISTICAL ANALYSIS CONVENTIONS 
 
6.1 Analysis Variables 
 
Baseline characteristics, medical history, vacci nation, immunogenicity (measurement of anti-HBs), 
concomitant medication, adverse events (AEs) and other safety assessments will be assessed according 
to the schedule of events listed as following : 
 
 
 
Screening 
Visit 
 
V1 
Safety 
Follow-up 
Phone Call 
 
V2 
Safety 
Follow-up 
Phone Call 
Safety 
Follow--up 
Phone Call 
 
V3 
Safety 
Follow-up 
Phone Call 
 
V4 ( I ) 
V5 
End of 
Study Visit 
Timelines (days) -28 0  28   168  196 336(a) 
Range (days) -28 
to 0  V1 
+ 5-9 -3/+7 V2 
+ 5-9 V2 
[PHONE_3517] +/-7 V3 
+ 5-9 +/-7 +/-14 
Screening           
Informed Consent X          
Physical Exam (b) X X  X   X  X X 
Medical History X          
Height and weight X          
Medications X          
HBV serology X          
HIV and HCV serology X          
Urine Pregnancy test X X  X   X    
Serum chemistry, 
hematology, HbA1C X          
Urinalysis X          
Inclusion & Exclusion 
Criteria X          
Confirmation of 
enrollment X X         
Vaccination  X  X   X    
Immunogenicity  X (c)     X (c)  X X 
Safety Assessments           
Vital signs X X (d)  X (d)   X (d)  X  
Subject instructed to 
complete diary  X X X X  X X   
Local & Systemic 
Reactions  X X(e) X X(e) X(e) X X(e)   
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 16 of 37  
  
Unsolicited Non Serious 
AEs  X X(g) X(g) X(g) X(g) X(f) X(g) X(g) X(f) 
Concomitant Medications X X X X X X X X X X 
Serious Adverse Events, 
Medically significant 
event and NOCI (h)  
Continuous 
Sub-Study (select sites )   A1*  A2*   A3*   
Serum chemistry, 
hematology  X (c) X(j)  X(j)   X(j)   
 (a) Or earlier in case of withdrawal (reason for withdrawal to be documented in eCRF) 
(b) Full physicals to be done at screening or pre-vaccination at Day 0. History-directed physicals can be completed at 
subsequent visits. 
(c) Blood sample will be taken before vaccination 
(d) Vital signs will be recorded before and 30 minutes after each vaccination. 
(e) Subjects will be instructed to record solicited and unso licited AEs. There will be a telephone call 7 days (+/-2 
days) after each vaccination, and 28 days (+/- 7 days) after the second vaccination to inquire about AEs. If there is a reaction the subject may be asked to come for a supplemental visit (not represented in this table) to assess 
severity at the discretion of the investigator. Follow-up until resolution. 
(f) Only AEs requiring medical attention 
(g) All AEs 
(h) NOCI = new onset of chronic illness 
(i) Visit [ADDRESS_184419] 3 weeks after Visit 3 
(j) Blood sample collected 7 days (-3/+7 days) after vaccination 
*Additional visits (A1, A2 and A3) required for study subjects at select sites participating in the clinical laboratory sub- 
study. 
 
 
6.1.1 Derived and Computed Variables 
 
Demographics 
Body Mass Index (BMI, kg/m2) will be calculated using the following formula: 
BMI = Weight (kg) / Height2 (m2) 
Immunogenicity 
Values below the lower limit of quantification (recorded as ‚Äú< LQ‚Äù) will be set to half that limit (LQ/2). 
Values above the upper limit of quan tification (recorded as ‚Äú>UQ‚Äù) w ill be set to that upper limit (UQ). 
Titer greater or equal to a given threshold is defined as binary variable for non-missing values as: 
= 1, if the titer is superior or equal to the given threshold 
= 0, otherwise 
Seroprotection is defined as binary variable for non-missing values as: 
= 1, if anti- +%VOHYHOV¬ïP,8P/LQVHUXP  
= 0, otherwise 
Seroprotection rate (SPR) is the percentage (%) of s ubjects achieving seroprotection. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 17 of 37  
 ¬¶ 10 i ¬∞n 
¬∞ 
An initial result of >=5.0 and <12.0 mIU/mL (‚ÄúIn determinate‚Äù) required  duplicate retest per 
Laboratory Procedure Manual. In the statistical an alysis, if the anti-HBs serology result is initially 
indeterminate, then the average of initial and repeat samples will be calculated. Seroprotection will be GHWHUPLQHGDVIROORZVLIWKHDYHUDJHRILQLWLDODQGUHSHDWVDP SOHVLV¬ïP,8P/WKHQLWZLOOEH
considered seroprotected. If it is less than 10 mIU/mL will be considered not seroprotected. 
Geometric Mean Concentration 
The GMC will be calculated using the following formula: 
¬≠ 
log    t ¬Ω
¬∞ i  1 ¬∞
¬Æ ¬æ
¬∞ n ¬∞
¬∞ ¬∞
10¬Ø ¬ø
where t1 ,t2 ,!,tnare n observed immunogenicity titers/concentrations. 
 
Solicited Adverse Events 
Reactions at the site of injection (redness/eryt hema, pain, tenderness, sw elling/edema, pruritus), 
systemic reactions (nausea/vomiting, diarrhea, headache, fatigue, myalgia) and vital signs 
abnormalities (fever, tachycardia,  bradycardia, hypertensions, hypot ension, changes in respi[INVESTIGATOR_862]). 
Unsolicited Adverse Events 
All adverse events will be characterized according to the date of occurrence related to the vaccination 
phase as follows: 
∆ì Emergence before vaccination phase : start date before the firs t date of injection of study 
vaccine. 
∆ì Emergence during vaccination phase : start date on or after the fi rst date of injection of study 
vaccine or, adverse event increase in severity including to ‚Äúserious‚Äù adverse event. 
If an adverse event start date is equal to the fi rst date of vaccination injection, missing or unknown, 
the adverse event will be considered as emergent. 
When start and/or end dates of an adverse even t are only partially known, adverse events will be 
categorized as emergent before, during (or after) vaccination phase using the following rules: 
∆ì,IWKHSDUWLDOHQGGDWHLVEHIRUHWKHILUVWVWXG\YDFFLQD WLRQLH\HDURU\HDU	PRQWKLVDUH
EHIRUHWKHILUVWVWXG\YDFFLQD WLRQ\HDURU\HDU	PRQWKWKHQW KHDGYHUVHHYHQWLVHPHUJHQWEHIRUH
vaccination phase. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 18 of 37  
 ∆ì ,IWKHSDUWLDOVWDUWGD WHLVHTXDORUDIWHU ¬ïWKHILUVWVWXG\ YDFFLQDWLRQLH\HDURU\HDU	PRQWK
LVDUHDIWHURUWKHVDPHDVW KHILUVWVWXG\LQMHFWLRQ\HDURU\ HDU	PRQWKWKHQWKHDGYHUVHHYHQWLV
emergent during vaccination phase. 
The maximum event severity is the greatest severity associated with a preferred term for a reported 
adverse event according to the following order: Mild < Moderate < Severe < Potentially life 
threatening. Unknown/ Missing severity is c onsidered as potentially life threatening. 
Multiple AEs with the same PT for th e same subject are counted only once. 
Vaccination-related Adverse Events are those for which the cause has been evaluated by [CONTACT_1275], and recorded either as very likely/ certain, possibly related, pr obably related or unknown/ 
missing. 
Pre-study, Concomitant and Post-Study Medications 
A pre-study medication is a medication used only before the first study vaccination (i.e. medication 
end date < first study vaccination date). 
A post-study medication is a medication used only after study te rmination (i.e. medi cation start date 
> study termination date). Th is will not be collected in the clinical  database and will not be reported in 
the CSR. 
All other medications are concomitant . 
When start and/or end dates of a medication intake are missing, th e medication is considered as 
concomitant with the study vaccination schedule. 
If the first study vaccination date is missing then the medication is considered as concomitant with the 
study vaccination schedule, provided that the st udy vaccine was administered to the subject. 
6.2 Analysis Sets 
6.2.1 All Enrolled Set 
 
The All Enrolled Set will be defined as all screened subjects who provide informed consent and provide 
demographic and/or baseline scre ening assessments, regardless of  the subject‚Äôs randomization and 
treatment status in the study. 
6.2.[ADDRESS_184420] will be assigne d according to the vaccination received. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 19 of 37  
 In case of vaccination error, subjects will be analyzed as initially ‚Äútreated‚Äù (i.e., according to the first 
vaccine a subject receives, rather than the vaccine to which the subject is randomized). 
6.2.3 Intent-to-Treat (ITT) 
 
All subjects in the All Enrolled Set who were randomized. 
In case of vaccination error, subjects in the ITT will be analyzed ‚Äúas randomized‚Äù (i.e., according to the 
vaccine a subject was designated to receive, which may be different from the vaccine the subject actually 
received). Any subject who received the wrong va ccination will not be excluded from the ITT. 
6.2.4 Full Analysis Set (FAS) 
 
All subjects in the All Enrolled Set who receive at least one vaccination and provide at least one evaluable 
serum immunogenicity sample both at  baseline and after baseline. 
In case of vaccination error, subjects in the FAS w ill be analyzed ‚Äúas randomi zed‚Äù (i.e., according to the 
vaccine a subject was designated to receive, which may be different from the vaccine the subject actually 
received). Any subject who received the wrong va ccination will not be excluded from the FAS. 
If a subject is unblinded during the study, he/she will be included in the FAS. 
 
6.2.5 Per Protocol Sets 
 
[IP_ADDRESS]  Per Protocol Set 1 (PPS1) 
 
All subjects in the FAS who: 
x received all [ADDRESS_184421]. 
These will be identified prior to unb linding and analysis and may include: 
x subjects enrolled who did not meet study entry criteria 
x subjects who did not receiv e the correct treatment 
x subjects who developed withdrawal criteria but were not withdrawn 
x subjects who received a prohibited concomitant medication 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/[ADDRESS_184422] immunogenicity results 
PPS1 will be used for the primary endpoint analysis. [IP_ADDRESS]  Per Protocol Set 2 (PPS2) 
 
All subjects in PPS1, but excluding those who attende d study visits outside of the following windows: 
x V3/Day 168 (+/- 28 days) 
x V4/Day 196 (-7/+14 days) 
PPS2 will be used for the primary, secondary, and exploratory endpoints. In case of vaccination error, subjects in PPS1 and/or PPS2 will be analyzed ‚Äúas randomized‚Äù and the 
subject who received the wrong vaccination will be excluded from PPS1 and/or PPS2. If a subject 
receives a vaccine from the wrong kit number, but th e same as the one the subject was randomized to, 
the subject will not be removed from PPS1 and/or PPS2. 
If a subject is unblinded during the study, except fo r suspected unexpected serious adverse reaction 
(S[LOCATION_003]R), he/she may be excluded from PPS1 and/or PPS2 based on sponsor‚Äôs decision with respect to 
any potential bias that may be introduced in th e analysis of the primary and key secondary 
immunogenicity analyses. 
6.2.6 Sub-study Analysis Set (SSA) 
 
All subjects in the All Enrolled Set who actually receive at least one dos e of study vaccination and 
participated in the clin ical laboratory sub-study. 
6.2.[ADDRESS_184423] will be pre-specified: 
x Gender (male vs female) 
x %0,¬îYV!  30) 
x Smoking Status (current vs past or non-smoker) 
x 'DLO\DOFRKROFRQVXPSWL RQ¬ïGULQNVGD\YV -3 drinks/day vs 0-1 drink/day) 
x Non-study licensed vaccine (no va ccination vs vaccination) 
x Race (White vs Black or African American vs Other) 
x Ethnicity (Hispanic or Latino vs Non Hispanic or Latino) 
x Country/region ([LOCATION_002] vs Canada vs Europe) 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/[ADDRESS_184424] eristics will be lis ted and described 
using summary statistics. Frequency counts (number of subjects [n] an d percentages) will be made for 
each qualitative variable. Descriptiv e statistics (n, mean, standard de viation [SD], median, minimum and 
maximum) will be calculated for each quantitative variable (unless otherwise stated). All listings will 
include repeated and unscheduled measurements. 
All descriptive statistics will be presented by [CONTACT_158787]. The baseline for all 
measurements (where applicable) will be the last pre-vaccination measurement. Descriptive statistics for 
all data obtained at Screening and follow-up will be presented separately. 
6.3.2 Statistical Significance Level 
 
All statistical tests will be two-sided and will be performed at the 5% level of significance, unless otherwise stated. 
 
6.3.3 Software 
 
All statistical analyses will be performed using Statistical Analysis Software (SAS¬Æ) Version 9.3 or later. 
 
6.3.4 Study Visits 
 
For laboratory data, vital si gn data and physical examin ation data, data will be summarized or listed using 
the scheduled visits (See Table 1 ). 
Table 1: Study Visits and Analysis Visits 
 
Nominal Study Visit Analysis Visit Target Study Day* 
Screening Screening -28 
Visit 1 Day 0 1 
Visit A1 Day 7 8 
Visit 2 Day 28 29 
Visit A2 Day 35 36 
Visit 3 Day 168 169 
Visit A3 Day 175 176 
Visit 4 Day 196 197 
Visit 5 Day 336 337 
Unscheduled Unscheduled  
* Study Day [ADDRESS_184425]. Study Day = (date of 
event/visit ‚Äì first vaccination date) if it is before the first vaccination. Study Day = (date of event/visit ‚Äì 
first vaccination date) + [ADDRESS_184426] vaccination. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/[ADDRESS_184427] the data to be included in the descriptive summary: 
x If multiple assessments occur within a given analysis  visit, the assessment closet to the target study 
day will be used for analysis purposes. 
x If there are [ADDRESS_184428] assessment, within 
the analysis visit, will be used in the analysis. 
6.3.5 Missing Data 
 
For immunogenicity data, it may be reasonable to consider missing immu nogenicity values as missing 
completely at random (MCAR), i.e., not informative. Therefore, each  of immunogenicity analyses will 
comprise a complete case analysis only, without in troducing any bias. Imputati on methods will not be 
used. 
6.3.6 Interim Analysis 
 
Not applicable. 
 
6.3.7 Protocol Deviations 
 
[IP_ADDRESS]  Definition of Protocol Deviation 
 
Deviations from the protocol will be assessed as ‚Äòminor‚Äô or ‚Äòmajor‚Äô. CSR reportable (‚Äúmajor‚Äù) protocol 
deviations (PDs) are defined in acco rdance with ICH E3 as important PDs related to study inclusion or 
exclusion criteria, conduct of the trial, subject management or subject assessment resulting in the 
potential to jeopardize the safety or rights of the trial subjects or the scientific value of the trial. 
All major PDs will be classified into the following categories, but not all deviations listed below will 
necessarily be declared a major PD: 
∆ì,QIRUPHG&RQVHQW  
∆ì,QFOXVLRQ([FOXVLRQFULWHULD  
∆ì:LWKGUDZDO&ULWHULD  
∆ì,QYHVWLJDWLRQDO3URGXF W,3$GPLQ6WXG\7UHDW  
∆ì'LVDOORZHG0HGLFDWLRQV  
∆ì$GYHUVH(YHQW$(6HULRXV$GYHUVH(YHQW6$(  
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 23 of 37  
 ∆ì Visit Schedule 
∆ì Procedure/Tests 
Major PDs may result in exclusions of subject fro m one or more analysis sets according to study- 
specific PD codes specifications. Majo r protocol deviations that may l ead to exclusion of the subject 
from PPS1 and/or PPS2 are defined in Section 6.2.5.  
The following PD summaries will be provided: 
x Number and percentage of subjects with a majo r protocol deviation by [CONTACT_158788] 
A by-patient listing of protocol deviations will be provided. 
 
[IP_ADDRESS]  Determination of Pr otocol Deviations 
 
Prior to unblinding, a PD report will be provided to the Clinical Study Team (CST) consisting of medical, 
clinical, and operational team me mbers from the Sponsor and CRO for review on an ongoing basis during 
the study. The PDs review is part of  the Data Listing Review process. 
After the review, the CST team is responsible fo r assessing the impact of PDs on the immunogenicity 
and safety data for study subjects from medical and c linical perspectives. The PDs will be identified and 
categorized to determine subjects to be exclude d from analysis populations according to the PDs 
specification. 
Details of PD review procedure will be provided in the Medical Monitoring Plan and Data Listing Review 
Manual. 
[IP_ADDRESS]  Exclusions of Individual Values for Safety Analysis 
 
Some local and systemic adverse events (AEs) will be directly measured by [CONTACT_158789] a reconciliation process, even if they are biologically implausible. Therefore, these implausible 
measurements will be removed from the analysis but included in listings. Implausible measurements are 
summarized in the Table 2 below: 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 24 of 37  
 Table 2: Implausible Solicited Adverse Events 
 
Parameter Implausible measurements 
Body temperature ¬î¬É&RU¬ï¬É&  
Erythema/Redness 0HDVXUHPHQWV¬ïPPRU
Measurements < 0 mm 
Induration/Swelling 0HDVXUHPHQWV¬ïPPRU
Measurements < [ADDRESS_184429] data will be presented overall as well as by [CONTACT_158790]-B-Vac‚Ñ¢ lot, Sci-B-Vac‚Ñ¢ 
treatment group and Engerix-B¬Æ tr eatment group (where possible): 
x The number of subjects screened (overall counts only) 
x The number of screen failures with a breakdown of reasons for screen failure (overall counts 
only) 
x The number of subject randomized 
x The number of subjects dosed. 
x The number and percentage of s ubjects who completed treatment 
x The number and percentage of subjects who di scontinued from treatment  with a breakdown of 
primary reasons for disc ontinuation from treatment 
x The number and percentage of subjects who completed study 
x The number and percentage of subjects who ter minated early. The number and percentage of 
subjects who withdrew early from study with a breakdown of primary reasons for the early 
withdrawal. 
Percentages of subjects will be ba sed on the number of subjects dosed as 100%. All enrolled set will be 
used for subject disposition. 
In addition, by-subject listings will be provided for subjects who discontinued the study early with reason 
for discontinuation. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 25 of 37  
 6.3.9 Demographic Data 
 
All demographic data will be presented for the ITT, FAS, PPS1, PPS2, Safety Set and SSA. All 
demographic and baseline characteristics will be listed and summarized by [CONTACT_158790]-B-Vac‚Ñ¢ lot, Sci-B- 
Vac‚Ñ¢ treatment group and Engeri x-B¬Æ treatment group using appropr iate descriptive statistics. 
Continuous data will be summarized using the num ber of observations, mea n, standard deviation, 
median, minimum and maximu m. Categorical data will be summ arized using frequency counts and 
percentages. No statistical hypot hesis testing w ill be conducted. 
6.3.10  Medical History 
 
The frequencies and percentages of subjects with medical history will be presented by [CONTACT_99129], by [CONTACT_158790]-B-Vac‚Ñ¢ lo t, Sci-B-Vac‚Ñ¢ treatment group and Engerix-B¬Æ 
treatment group. Medical history data will be tabulated  for the ITT, FAS, PPS1, PPS2 and Safety Set. 
6.3.11  Concomitant Medication 
 
Concomitant medication will be summarized and listed for Safety Set. The frequencies and percentages 
of subjects reporting concomitant medications will be tabulated by [CONTACT_158790]-B-Vac‚Ñ¢ lot, Sci-B-Vac‚Ñ¢ treatment group and Engerix-B¬Æ trea tment group. Medications (generic  drug name) will be coded using 
the WHO Drug dictionary. 
Prior and concomitant proce dures/non-drug therapi[INVESTIGATOR_158774] a listing. 
6.3.[ADDRESS_184430] vaccination and the number of 
subjects received only 1 vaccination, onl y 2 vaccinations and all three va ccinations will be summarized 
by [CONTACT_158790]-B-Vac‚Ñ¢ lot, Sci-B-Vac‚Ñ¢  treatment group and Engerix-B¬Æ  treatment group for safety 
population. 
Vaccine administration inform ation will also be listed. 
 
6.3.13  Immunogenicity 
 
The primary analysis of the immunogenicity data will be based on PPS1 and PPS2. Sensitivity analyses 
using the same modeling approach will be conducted using the FAS. These analyses will be reported 
both with and without patients in the FAS who are seropositive at baseline. 
Immunogenicity (measurement of anti-HBs titer) da ta will be listed by [CONTACT_158791]. Se rum concentrations will be summa rized by [CONTACT_158790]-B-Vac‚Ñ¢ lot, Sci- 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 26 of 37  
 B-Vac‚Ñ¢ treatment group and Enge rix-B¬Æ treatment group. The followi ng descriptive st atistics will be 
presented for serum concentrations obtained at each time point: n, geometric mean, geometric SD, median, minimum and maximum values. 
Individual serum concentration versus actual times will be plotted by [CONTACT_158790]-B-Vac‚Ñ¢ lot, Sci-B-Vac‚Ñ¢ 
treatment group and Engerix-B¬Æ tr eatment group for anti-HBs antibody in linear and semi-logarithmic 
scale. The geometric mean serum concentrations with corresponding 95%  confidence intervals versus 
times will also be presented . The bar plot of SPR  by [CONTACT_158792] 16 8, 196 and 336 will also be 
produced based on PPS2. All tr eatment groups will be ove rlaid on the same plot. 
[IP_ADDRESS]  Primary Hypothesis 
 
The lot-to-lot equivalence, in term s of immunogenicity, of three independe nt consecutive lots of the Sci- 
B-Vac‚Ñ¢ will be demonstrated if the following condition is satisfied: 
The upper and lower bound of the two sided 95% CI of  the geometric mean concentration (GMC) of 
anti-HBsAg antibody ratios [ADDRESS_184431] injection for all three pairwise comparisons 
(GMC(group A)/GMC(group B), GMC(group A)/GMC(group C), GM C(group B)/GMC(group C)) are 
within [0.67, 1.5] 
The analysis will use a two-sided 5% significance level. PPS1 and PPS2 will be used to test the primary 
hypothesis. 
[IP_ADDRESS]  Statistical Methods for Primary Immunogenicity Analyses 
 
Geometric mean concentration (G MC) of anti-HBsAg antibody ratios [ADDRESS_184432] injection 
 
All statistical analyses will be performed on the logarithmically (base 10) transformed values. 
 
Adjusted estimates of GMCs and their associated 95% CIs will each be determined using an analysis of 
covariance (ANCOVA) model with a factor for vaccine lot group, and a covariate for the log transformed 
pre-vaccination (baseline) titer. Da ta from all centers w ill be pooled. For each vaccine lot, antibody 
GMCs, associated standard errors, two-sided 95% CIs and median, minimum, and maximum titer values 
will be determined and presente d by [CONTACT_158793]. The median, minimum,  and maximum values will be 
reported on the actual titer values, rather than the log scale. The ratio in GMCs between each vaccine lot 
group (GMC(group A)/GMC(group B), GMC(group A)/GMC(group C), GMC(group B)/GMC(group 
C)), and their associated two-sided 95% CIs will also be presented. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 27 of 37  
 Sensitivity analyses using the same modeling approach  outlined above will be conducted using the FAS. 
These analyses will be reported both with and w ithout patients in the FAS who are seropositive at 
baseline. 
If this condition is satisfied with either PPS1 or PPS2, then manufacturing equivalence (lot-to-lot 
consistency) will be demonstrated. 
Sample SAS code for assessment  of lot-to-lot equivalence: 
x Sample SAS code for ANCOVA model: 
PROC MIXED; 
CLASS treatment; 
MODEL log (var) = treatment log (baseline of var); 
LSMEANS treatment / DIFF CL ALPHA=0.05; 
ODS OUTPUT LSMEANS=ls_means Diffs=diff; 
QUIT; 
where var represent the anti-HBs titer and treatme nt represents vaccine lot group. 
 
 
[IP_ADDRESS]  Secondary Objective Analyses 
 
If lot-to-lot consistency is demonstrated, then the data from the three lots will be combined to address 
the secondary immunogenicity non inferior ity-hypothesis. It is to demons trate that the SPR 4 weeks after 
completion of the three-dose regime n of Sci-B-Vac‚Ñ¢ is non-inferior to  the SPR 4 weeks after completion 
of a three-dose regimen of Engerix-B¬Æ . Seroprotection is defined as anti- +%VOHYHOV¬ïP,8P/  in 
serum. Seroprotection rate (SPR) is the percen tage (%) of subjects achieving seroprotection. 
Seroprotection rate (SPR) [ADDRESS_184433] injection 
 
Non-Inferiority of Sci-B-Vac‚Ñ¢ [ADDRESS_184434] vaccination compared to Engerix-B¬Æ [ADDRESS_184435] vaccination will be assessed using PPS2. Data from all centers will be pooled 
and data from all 3 lots of Sci-B-Vac‚Ñ¢ will be pooled. The differ ence in proportions [SPR(Sci-B-Vac‚Ñ¢) 
‚ÄìSPR(Engerix-B¬Æ)] and two-sided 95% CIs, will be calculated using the Miettinen and Nurminen 
method. Funnel plot will be produced to  investigate the impact of center. 
Sample SAS code for asse ssment of non-inferiority: 
 
x Sample SAS code for the analysis of binary data: 
PROC FREQ; * specify and sub-se lect data set as applicable; 
TABLES trt*seroprotection/riskdiff (cl=mn); * numerical 0/1-scores identify ‚Äòevent‚Äô; 
RUN; 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 28 of 37  
 where seroprotection represent the seropositiv e event and trt represents treatment group. 
If the lower bound of the 95% Miettinen-Nurminen CI is  greater than -5%, Sci-B-Vac‚Ñ¢ will be declared 
non-inferior to Engerix-B¬Æ. 
Sensitivity analyses using the same modeling appro ach outlined above will be conducted using the FAS 
and ITT. For these ITT analyses, patients with missi ng data at Day 196 ([ADDRESS_184436] 
vaccination) will be included and treated as failur es. These analyses will be reported both with and 
without patients who are seropositive at baseline. 
[IP_ADDRESS]  Exploratory Obj ective Analyses 
 
Analysis of all exploratory immunoge nicity endpoints will be based on PPS2, unless otherwise indicated. 
Exploratory efficacy endpoints will be summarized and analyzed without adjustment for multiple 
comparisons. 
Each of the exploratory endpoints defined in the prot ocol will be summarized for each Sci-B-Vac‚Ñ¢ lot 
separately, as well as for the difference between each Sci-B-Vac‚Ñ¢ lot. Analysis of GMC endpoints will use the same methods as described above for the pr imary endpoint. For binary data, proportions and two- 
sided 95% CIs will be reported. The difference in pr oportions and two-sided 95% CIs, will be calculated 
using the Miettinen and Nurminen method. 
In addition, each of the exploratory endpoints will be  summarized with data fro m all 3 lots of Sci-B- 
Vac‚Ñ¢ pooled together. Summaries will be pres ented for Sci-B-Vac‚Ñ¢, E ngerix-B‚Ñ¢ and for the 
treatment difference. Adjusted estimates of GMCs and their associated 95% CIs will each be determined 
using an analysis of covariance (ANCOVA) model with a factor for treatment group, and a covariate for 
the log transformed pre-vaccination (baseline)  titer. For each treatment group, anti-HBs GMCs, 
associated standard errors, two-sided 95% CIs and median, minimum, and maximum titer values will be 
determined and presented by [CONTACT_12922]. The median, minimum, and maximum values will be 
reported on the actual titer values, rather than the log scale. The ratio in GMCs between treatment groups 
(GMC of anti-HBs in Sci-B-Vac‚Ñ¢ / GMC of anti-HBs in Engerix-B¬Æ), and their associated two-sided 
95% CIs will also be presented. For binary data, proportions and two-sided 95% CIs will be reported. 
The difference in proportions and two-sided 95% CIs, will be calculated using the Miettinen and 
Nurminen method. 
Please see Section [IP_ADDRESS] and Section [IP_ADDRESS] for sample codes. Per sponso r‚Äôs request, one additional 
pre-specified exploratory analysis has been added to the SAP. This additional exploratory analysis is as 
follows: 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 29 of 37  
 x To determine whether the SPR after 2 vaccinations with Sci-B-Vac‚Ñ¢, evaluated 20 weeks after the 
second vaccination (just prior to receiving the thir d vaccination), is non-inferior to the SPR [ADDRESS_184437] vaccination with Engerix-B¬Æ. 
This additional exploratory analysis will be summarized with data from all 3-lots of Sci-B-Vac‚Ñ¢ pooled 
together. 
6.3.[ADDRESS_184438] safety 
variables will be based on the Safety Set. Data from each Sci- B-Vac‚Ñ¢ lot will be presented both 
individually as well as pooled toge ther, while data from Engerix-B¬Æ  will be presented separately. 
[IP_ADDRESS]  Completer Analysis on Solicited Adverse Events 
 
Solicited adverse events 
 
The safety completeness analysis on solicited adverse events aims to identify subjects who completed 
diary cards and/or remained in clinic for at leas t [ADDRESS_184439] and/or 
[ADDRESS_184440] each vaccination assessment (including implausible values) except ‚ÄúNot 
done/unknown‚Äù. 
Three summaries will be produced: 
 
1. The frequencies of subjects who pr ovide diary cards by [CONTACT_29299]. 
 
2. For each type of solicited adverse event (local , systemic, other), the frequencies of subjects 
with valid data by [CONTACT_29299], aggregated ov er time points and interv als: 0-30 min (clinic), 
>30 min ‚Äì Day 1 (diary), Day 2 ‚Äì 7 (diary). wh ere the Day 1 is the date of each vaccination. 
The Day value is incremented by 1 for each date following the date of the vaccination. 
3. For each solicited adverse event, the frequencie s of subjects with valid data by [CONTACT_158794]: 0-30 min (clinic), >30 min ‚Äì Day 1 (diary), Day 2 ‚Äì 7 (diary) where the Day [ADDRESS_184441] was present or not. All 
analyses will be based on the Safety Set (i.e. ‚Äòas treated‚Äô). 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 30 of 37  
 [IP_ADDRESS]  Solicited Local, Systemic and Other Adverse Events 
 
The following solicited local and systemic adverse even ts as well as solicited other adverse events will 
be collected. The grading of sever ity will be graded according to the FDA Guidance for Industry Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical 
Trials (2007) ‚Äì also see protocol Appendix 2. 
Solicited local adverse events: 
‚Ä¢ Redness/erythema 
‚Ä¢ Pain 
‚Ä¢ Swelling/edema 
‚Ä¢ Tenderness 
‚Ä¢ Pruritus 
 
 
Injection site reactions grading 
 Grade 1 Grade 2 Grade 3 Grade 4 
 
Pain (pain without 
touching)  
Does not 
interfere with activity  
Repeated use of non- narcotic pain reliever > 24 hours or interferes with 
activity  
Any use of 
narcotic pain reliever or prevents daily activity  
Emergency room (ER) visit or hospi[INVESTIGATOR_158775] 
(pain when area is 
touched)  
Mild 
discomfort to 
touch  
Discomfort 
with 
movement  
Significant 
discomfort 
at rest  
ER visit or 
hospi[INVESTIGATOR_158776]. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 31 of 37  
  
 
Pruritus associated 
with injection See also Skin: 
Pruritus (itching - no skin lesions)  
Itching localized to injection site AND Relieved spontaneously or with 
< 48 hours 
treatment  
Itching 
beyond the injection site but not generalized OR Itching localized to injection site UHTXLULQJ¬ï48 hours 
treatment  
Generalized 
itching 
 
causing 
inability to perform usual social 	functional activities  
NA 
 
Erythema/Redness 
*  
2.5 ‚Äì 5 cm  
5.1 ‚Äì 10 cm  
> 10 cm  
Necrosis or exfoliative 
dermatitis 
 
Induration/Swelling 
**  
2.5 ‚Äì 5 cm 
and does not interfere with activity  
5.1 ‚Äì 10 cm or interferes 
with 
activity  
> 10 cm or 
prevents daily activity  
Necrosis 
*In addition to grading the measured local reaction at  the greatest single di ameter, the measurement 
should be recorded as a continuous variable. 
** Induration/Swelling should be evaluated and graded us ing the functional scale as well as the actual 
measurement. 
 
Solicited systemic adverse events: 
‚Ä¢ Nausea/vomiting 
‚Ä¢ Diarrhea 
‚Ä¢ Headache 
‚Ä¢ Fatigue 
‚Ä¢ Myalgia 
 
The grading of systemic adverse events will be as follows: 
 
Systemic 
(General) Mild 
(Grade 1) Moderate 
(Grade 2) Severe 
(Grade 3) Potentially Life 
Threatening 
(Grade 4) 
Nausea/vomiting No interference 
with activity or 1 
- 2 epi[INVESTIGATOR_1841]/24 
hours Some 
interference with 
activity or > 2 Prevents daily 
activity, requires 
outpatient IV 
hydration ER visit or 
hospi[INVESTIGATOR_158777]. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 32 of 37  
  
  epi[INVESTIGATOR_1841]/24 
hours   
Diarrhea 2 - 3 loose stools 
or < 400 g/24 
hours 4 - 5 stools or 
400 - 800 g/24 
hours 6 or more 
watery stools or 
> 800g/24 hours 
or requires 
outpatient IV 
hydration ER visit or 
hospi[INVESTIGATOR_158778]-narcotic 
pain reliever > 
24 hours or some 
interference with 
activity Significant; any 
use of narcotic 
pain reliever or 
prevents daily 
activity ER visit or 
hospi[INVESTIGATOR_158779]; 
prevents daily 
activity ER visit or 
hospi[INVESTIGATOR_158780]; 
prevents daily 
activity ER visit or 
hospi[INVESTIGATOR_158781]: 
‚Ä¢ Fever 
‚Ä¢ Tachycardia - beats per minute (0-30 min only) 
‚Ä¢ Bradycardia - beats per minute (0-30 min only) 
‚Ä¢ Hypertension (0-30 min only) 
‚Ä¢ Hypotension (0-30 min only) 
‚Ä¢ Respi[INVESTIGATOR_697] (0-30 min only) 
The grading will be as follows: 
Vital Signs * Mild 
(Grade 1) Moderate 
(Grade 2) Severe 
(Grade 3) Potentially Life 
Threatening 
(Grade 4) 
)HYHU¬É&


¬É)
  38.0 ‚Äì 38.4 
00.4 ‚Äì 101.1 38.5 ‚Äì 38.9 
101.2 ‚Äì 102.0 1. 39.0 ‚Äì 40 
2. 102.1 ‚Äì 104 > 40 
> 104 
Tachycardia - beats 
per minute 101 ‚Äì 115 116 ‚Äì 130 > 130 ER visit or 
hospi[INVESTIGATOR_151620] - beats 
per minute*** 50 ‚Äì 54 45 ‚Äì 49 < 45 ER visit or 
hospi[INVESTIGATOR_158782]. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 33 of 37  
  
Hypertension 
(systolic) - mm Hg 141 ‚Äì 150 151 ‚Äì 155 > 155 ER visit or 
hospi[INVESTIGATOR_151622] 
(diastolic) - mm Hg 91 ‚Äì 95 96 ‚Äì 100 > 100 ER visit or 
hospi[INVESTIGATOR_151623] (systolic) 
‚Äì mm Hg 85 ‚Äì 89 80 ‚Äì 84 < 80 ER visit or 
hospi[INVESTIGATOR_151624] ‚Äì breaths per minute 17 ‚Äì 20 21 ‚Äì 25 > [ADDRESS_184442] for all vital sign measurements. 
** Oral temperature; no recent hot or cold beverages or smoking. *** When resting heart rate is between [ADDRESS_184443] populations, for example, conditioned 
athletes. 
 
All solicited AEs will be summarized according to defined severity grading scales. Frequencies and 
percentages of subjects experiencing each solicited AE  will be presented for each symptom, by [CONTACT_158795] (i .e., after each vaccination). 
[IP_ADDRESS]  Unsolicited Adverse Events 
 
Treatment-emergent adverse events (TEAEs) are define d as those adverse events that either start or 
worsen on or after the date of first vaccination. 
All following TEAEs will be included in the summary tables: 
 
x All AEs occurred on the day of vaccination (va ccination 1, vaccination 2 or vaccination 3) and 
during the next 27 days [date of vaccination + 27 days] 
AND 
 
x SAEs, medically significant events (i.e., AEs me dically attended) or new onset of chronic 
illnesses through the date of end study 
If a subject missed one or two vaccination injec tions, the AEs for the corresponding vaccination 
injections will not be included in the summary. Fo r example, one subject mis sed vaccination 2, the AEs 
for the day of vaccination 2 and during the next 27 days will be missing and not be included in the 
summary tables and figures. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 34 of 37  
 Solicited adverse events continui ng beyond Day 7 will be coded by [CONTACT_158796]. 
For AEs included in the summary tables defined a bove, numbers of AEs will be summarized by [CONTACT_86104] (SOC) and Preferred Term, and also by [CONTACT_926]/causality to vaccine. The summaries will 
be presented by [CONTACT_33853] (any vaccination, vaccinati on 1, vaccination 2 and vaccination 3) and interval 
of onset as follow: 
x Day 1 to Day 28 
where the AEs will include AEs occurred on/after Day 1 (date of vaccination) until earliest date 
of (Day 28, date of next vaccination-1, end of study) 
x Day 29 to end of considered interval 
where the AEs will include SAEs, medically significant events (i.e., AEs medically attended) or new onset of chronic illnesses occurred on/after Day [ADDRESS_184444] date of (date of next vaccination-1, end of study) 
x Day 1 to end of considered interval 
where the AEs will include AEs occurred on/after Day 1 (date of vaccination) until earliest date 
of (date of next vaccination-1, end of study) 
The original verbatim terms used by [CONTACT_158797] (MedDRA) dictionary. The AEs 
will then be grouped by [CONTACT_158798]. 
These summaries will be presented by [CONTACT_6654]. When an AE occurs more than once 
for a subject, the maximal severity  and strongest relationship to th e treatment group will be counted. 
Separate summaries w ill be produced for the following categories: 
- AEs 
- SAEs 
- Unexpected AEs 
- AEs that are very likely, probably or possibly related to vaccine 
- AEs leading to vaccine withdrawal 
- AEs leading to study withdrawal 
- AEs medically attended 
- New onset of chronic illnesses 
- Solicited AEs continuing beyond Day 7 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/[ADDRESS_184445] vaccination through the date of end study will be 
summarized by [CONTACT_6213] s into frequency tables according to system organ class for the 
following categories: 
- AEs 
- SAEs 
- AEs leading to vaccine withdrawal 
- AEs leading to study withdrawal 
- New onset of chronic illness 
- AEs medically attended 
 
The following listings will be produced: 
 
x All pre-vaccination AEs and TEAEs 
x AEs leading to vaccine withdrawal 
x AEs leading to study withdrawal 
x SAEs 
x AEs medically attended 
x New onset of chronic illnesses 
x Solicited AEs continuing beyond Day 7 
x AEs leading to death 
 
[IP_ADDRESS]  Clinical Safety Laboratory Tests (Hem atology, Biochemistry and Urinalysis) 
 
Laboratory values (hematology, biochemistry and ur inalysis) will be listed by [CONTACT_158799] (with the excepti on of urinalysis). The baseline for the laboratory 
values will be the latest non-missing result obtained befo re first vaccine injection. 
All laboratory (e.g., hematology, bioc hemistry) data will be summarize d using descriptive statistics. 
Summaries will be provided for the observed values and changes from baseline at each scheduled visit. The changes in biochemistry and hematology from baseline will only be  calculated in the clinical 
laboratory sub-study analysis set ( SSA). In addition, absolute and ch ange from baseline values will be 
categorized according to the toxicity scales (See protocol Appendix 3 for la boratory parameters) and 
summarized by [CONTACT_158800]. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 36 of 37  
 [IP_ADDRESS]  Vital Signs 
 
Vital signs data will be listed by [CONTACT_158801] e. The baseline for the vital signs 
measurements will be the late st non-missing results obtained be fore first vaccine injection. 
All vital sign data will be summarized using descriptive statistics. Summaries will be provided for the 
observed values and changes from ba seline at each scheduled visit. In  addition, absolute and change 
from baseline values will be categorized according to the toxicity scales (see protocol Appendix 3 for 
vital signs) and summarized by [CONTACT_158800]. 
[IP_ADDRESS]  Physical Examination 
 
The results of the physical examina tion will be listed by [CONTACT_158802] -point. Any clinically significant 
difference in physical examination from prev ious visit will be summarized by [CONTACT_765]. 
PAREXEL International 
Statistical Analysis Plan 
VBI Vaccines Inc. 
Sci-B-Vac‚Äì002  Final 2.0 
04/Dec/2019 
Page 37 of 37  
 7. REFERENCES 
1. SAS¬Æ Version 9.3 of the SAS System for Personal Computers. Copyright ¬© 2002-2010. SAS Institute 
Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or 
trademarks of SAS Institute Inc., Cary, NC, [LOCATION_003]. 
2. Protocol version 4.0 
 
Document ID: 551878464 - Name [CONTACT_158803]: 233961_SAP_20191204_2.0.pdf 
This document contains a total of 38 pages including any signature [CONTACT_3264]/s. 
 
 
 
PAREXEL International Electronic Signature [CONTACT_158804] c signature(s) used in compliance with PAREXEL 
International‚Äôs electronic signature [CONTACT_158805]. 
 
 
  
 
UserName: [CONTACT_158806], Andreana (robertan) 
Title: Principal Biostatistician, GDO 
Date: Wednesday, 04 December 2019, 11:[ADDRESS_184446] Time 
Meaning: Document contents approved. 
================================================ 